Literature DB >> 35900341

SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats.

Takahiro Masuda1, Ken Ohara1, Volker Vallon2, Daisuke Nagata1.   

Abstract

Loop diuretics are commonly used diuretics in the treatment of fluid retention but induce hypovolemia-related renal dysfunction. Na+-glucose cotransporter 2 (SGLT2) inhibitors induce osmotic diuresis, but body fluid volume is maintained by stimulating vasopressin-induced fluid intake and collecting duct water reabsorption as previously reported in diabetic rats. We aimed to test the hypothesis that unlike SGLT2 inhibitors, loop diuretics lack activation of similar fluid homeostatic mechanisms. Nondiabetic male Sprague-Dawley rats were treated daily by oral gavage with vehicle, the SGLT2 inhibitor ipragliflozin (5 mg/kg), or the loop diuretic furosemide (50 mg/kg) and monitored in metabolic cages for 2 or 7 days. Ipragliflozin and furosemide similarly increased urine volume on day 2. This was associated with increased serum Na+ concentration, urine vasopressin excretion, fluid intake, and solute-free water reabsorption in response to ipragliflozin but not to furosemide. Ipragliflozin maintained fluid balance (fluid intake - urine volume) on day 2 and total body water measured by bioimpedance spectroscopy and serum creatinine on day 7. In comparison, furosemide decreased fluid balance on day 2 and decreased total body water and increased serum creatinine on day 7. Furosemide, but not ipragliflozin, increased plasma renin activity, and systolic blood pressure was similar among the groups. In conclusion, the osmotic diuresis of the SGLT2 inhibitor increased serum Na+ concentration and the vasopressin-related stimulation of fluid intake and renal water retention maintained fluid balance, whereas the loop diuretic did not engage the compensatory vasopressin system. The data suggest differences in vasopressin and fluid homeostatic responses between SGLT2 inhibitors and loop diuretics.NEW & NOTEWORTHY In nondiabetic rats, the Na+-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin increased vasopressin-related stimulation of fluid intake and free water reabsorption and maintained fluid balance and serum creatinine, whereas the loop diuretic furosemide reduced vasopressin and induced a negative fluid balance followed by a subsequent increase in serum creatinine. This study suggests that differences in vasopressin secretion in response to a SGLT2 inhibitor or loop diuretic may contribute to differences in body fluid status and subsequent renal function.

Entities:  

Keywords:  fluid homeostasis; fluid intake; loop diuretic; sodium-glucose cotransporter 2 inhibition; vasopressin

Mesh:

Substances:

Year:  2022        PMID: 35900341      PMCID: PMC9423725          DOI: 10.1152/ajprenal.00070.2022

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  44 in total

Review 1.  Everything we always wanted to know about furosemide but were afraid to ask.

Authors:  Xiaohua Huang; Evert Dorhout Mees; Pieter Vos; Shereen Hamza; Branko Braam
Journal:  Am J Physiol Renal Physiol       Date:  2016-02-24

2.  Osmolality-induced changes in aldosterone secretion involve a chloride-dependent process.

Authors:  N Hayama; W Wang; E G Schneider
Journal:  Am J Physiol       Date:  1995-01

3.  Chronic hyperosmotic stress converts GABAergic inhibition into excitation in vasopressin and oxytocin neurons in the rat.

Authors:  Jeong Sook Kim; Woong Bin Kim; Young-Beom Kim; Yeon Lee; Yoon Sik Kim; Feng-Yan Shen; Seung Won Lee; Dawon Park; Hee-Joo Choi; Jinyoung Hur; Joong Jean Park; Hee Chul Han; Christopher S Colwell; Young-Wuk Cho; Yang In Kim
Journal:  J Neurosci       Date:  2011-09-14       Impact factor: 6.167

Review 4.  Tubular Transport in Acute Kidney Injury: Relevance for Diagnosis, Prognosis and Intervention.

Authors:  Volker Vallon
Journal:  Nephron       Date:  2016-05-31       Impact factor: 2.847

5.  Osmotic control of vasopressin release by rat hypothalamo-neurohypophyseal explants in organ culture.

Authors:  C D Sladek; K M Knigge
Journal:  Endocrinology       Date:  1977-12       Impact factor: 4.736

6.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

7.  Dapagliflozin in Patients with Chronic Kidney Disease.

Authors:  Hiddo J L Heerspink; Bergur V Stefánsson; Ricardo Correa-Rotter; Glenn M Chertow; Tom Greene; Fan-Fan Hou; Johannes F E Mann; John J V McMurray; Magnus Lindberg; Peter Rossing; C David Sjöström; Roberto D Toto; Anna-Maria Langkilde; David C Wheeler
Journal:  N Engl J Med       Date:  2020-09-24       Impact factor: 91.245

8.  Osmoregulation of thirst and vasopressin secretion in human subjects: effect of various solutes.

Authors:  R L Zerbe; G L Robertson
Journal:  Am J Physiol       Date:  1983-06

9.  Effect of 3% saline and furosemide on biomarkers of kidney injury and renal tubular function and GFR in healthy subjects - a randomized controlled trial.

Authors:  F H Mose; A N Jörgensen; M H Vrist; N P Ekelöf; E B Pedersen; J N Bech
Journal:  BMC Nephrol       Date:  2019-06-03       Impact factor: 2.388

10.  The cellular basis of distinct thirst modalities.

Authors:  Allan-Hermann Pool; Tongtong Wang; David A Stafford; Rebecca K Chance; Sangjun Lee; John Ngai; Yuki Oka
Journal:  Nature       Date:  2020-10-14       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.